<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Transgenic mice bearing a murine immunoglobulin enhancer/c-myc fusion transgene (Emu-myc) provide a useful model for Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Groups of 12 Emu-myc mice were treated prophylactically for 6 weeks after weaning with anti-c-myc DNA phosphorothioate (20 mg/kg/day), scrambled control DNA, or saline, delivered by micro-osmotic pumps </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Half of the mice treated with saline or scrambled control DNA displayed palpable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> by 8-9 weeks after birth, and 95% of them did so by 16 weeks, but 75% of the mice treated with antisense DNA were still free of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> at the age of 26 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Antisense therapy ablated MYC antigen in the spleens of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing mice </plain></SENT>
<SENT sid="4" pm="."><plain>Plasma physiological parameters indicated no <z:hpo ids='HP_0011009'>acute</z:hpo> toxicity </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Long-term <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> resistance after anti-c-myc DNA therapy implies induction of a host response </plain></SENT>
<SENT sid="6" pm="."><plain>Prophylactic anti-c-myc DNA therapy might prevent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in asymptomatic individuals displaying c-myc translocations </plain></SENT>
</text></document>